Compare Stocks: CHRS, CLYM, AURA, and DBVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.54 +0.5%	$7.08	$4.73 ▼ $9.53	$678.23M	0.41	1.05 million shs	962,556 shs
CHRS Coherus Oncology	$1.07	$1.28	$0.97 ▼ $2.62	$165.32M	0.98	1.68 million shs	1.70 million shs
CLYM Climb Bio	$11.00 +1.3%	$13.98	$1.63 ▼ $18.33	$631.80M	-0.04	1.49 million shs	638,005 shs
DBVT DBV Technologies	$9.80 +2.6%	$12.87	$9.36 ▼ $26.18	$616.20M	-1.04	474,307 shs	324,040 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+0.46%	+7.39%	-9.17%	-4.39%	+7.39%
CHRS Coherus Oncology	0.00%	-7.76%	-18.94%	-30.52%	-39.20%
CLYM Climb Bio	+1.29%	+0.55%	-26.91%	-21.43%	+511.11%
DBVT DBV Technologies	+2.62%	-7.11%	-27.08%	-40.57%	-38.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.54 +0.5%	$7.08	$4.73 ▼ $9.53	$678.23M	0.41	1.05 million shs	962,556 shs
CHRS Coherus Oncology	$1.07	$1.28	$0.97 ▼ $2.62	$165.32M	0.98	1.68 million shs	1.70 million shs
CLYM Climb Bio	$11.00 +1.3%	$13.98	$1.63 ▼ $18.33	$631.80M	-0.04	1.49 million shs	638,005 shs
DBVT DBV Technologies	$9.80 +2.6%	$12.87	$9.36 ▼ $26.18	$616.20M	-1.04	474,307 shs	324,040 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+0.46%	+7.39%	-9.17%	-4.39%	+7.39%
CHRS Coherus Oncology	0.00%	-7.76%	-18.94%	-30.52%	-39.20%
CLYM Climb Bio	+1.29%	+0.55%	-26.91%	-21.43%	+511.11%
DBVT DBV Technologies	+2.62%	-7.11%	-27.08%	-40.57%	-38.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	2.33	Hold	$17.50	167.58% Upside
CHRS Coherus Oncology	2.33	Hold	$11.00	928.04% Upside
CLYM Climb Bio	3.00	Buy	$27.62	151.05% Upside
DBVT DBV Technologies	2.67	Moderate Buy	$48.50	394.90% Upside

Current Analyst Ratings Breakdown

Latest CHRS, CLYM, AURA, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
10/5/2026	CLYM Climb Bio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$34.00
9/30/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/22/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D-)
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
CHRS Coherus Oncology	$42.17M	3.92	N/A	N/A	$0.50 per share	2.14
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DBVT DBV Technologies	$5.64M	109.26	N/A	N/A	$4.20 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	11/12/2026 (Estimated)
CHRS Coherus Oncology	$168.02M	-$1.03	N/A	N/A	N/A	-259.41%	-222.75%	-52.11%	11/5/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)

Latest CHRS, CLYM, AURA, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CHRS Coherus Oncology	-$0.21	N/A	N/A	N/A	$15.98 million	N/A
10/28/2026	Q3 2026	DBVT DBV Technologies	-$0.1617	N/A	N/A	N/A	$0.66 million	N/A
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.25	-$0.19	+$0.06	-$0.13	$14.41 million	$14.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	16.82	16.82
CHRS Coherus Oncology	0.61	1.77	1.70
CLYM Climb Bio	N/A	31.45	31.45
DBVT DBV Technologies	N/A	3.72	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CHRS Coherus Oncology	72.82%
CLYM Climb Bio	69.76%
DBVT DBV Technologies	71.74%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	1.90%
CHRS Coherus Oncology	7.22%
CLYM Climb Bio	2.60%
DBVT DBV Technologies	1.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	113	103.71 million	101.74 million	Not Optionable
CHRS Coherus Oncology	144	154.50 million	143.35 million	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable

CHRS, CLYM, AURA, and DBVT Headlines

Recent News About These Companies

DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low - Here's Why

October 8 at 4:01 AM | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low - Time to Sell?

October 8 at 3:59 AM | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low - Time to Sell?

October 2, 2026 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Here's What Happened

October 1, 2026 | marketbeat.com

DBV Technologies ADR (DBVT)

September 30, 2026 | za.investing.com

DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children

September 30, 2026 | rttnews.com

DBV Technologies Submits US FDA Application for Potential Pediatric Peanut Allergy Patch

September 30, 2026 | finance.yahoo.com

DBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut Allergy

September 29, 2026 | rttnews.com

DBV Technologies S.A.: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years

September 29, 2026 | finanznachrichten.de

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

September 29, 2026 | finance.yahoo.com

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

September 29, 2026 | globenewswire.com

DBV Technologies (NASDAQ:DBVT) Shares Up 4.9% - Here's What Happened

September 28, 2026 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Trading Down 7.1% - Should You Sell?

September 24, 2026 | marketbeat.com

DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Rating of "Moderate Buy" by Brokerages

September 20, 2026 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - What's Next?

September 16, 2026 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Trading Down 7.4% - Here's Why

September 11, 2026 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below 200-Day Moving Average - What's Next?

September 11, 2026 | marketbeat.com

DBV Technologies to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

September 2, 2026 | globenewswire.com

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

July 30, 2026 | globenewswire.com

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

July 26, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CHRS, CLYM, AURA, and DBVT Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.54 +0.03 (+0.46%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.52 -0.01 (-0.23%)

As of 10/9/2026 07:30 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Coherus Oncology NASDAQ:CHRS

$1.07 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.09 +0.02 (+1.87%)

As of 10/9/2026 07:45 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Climb Bio NASDAQ:CLYM

$11.00 +0.14 (+1.29%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.80 -0.20 (-1.85%)

As of 10/9/2026 07:30 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

DBV Technologies NASDAQ:DBVT

$9.80 +0.25 (+2.62%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.80 +0.00 (+0.05%)

As of 10/9/2026 06:43 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, CLYM, AURA, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, CLYM, AURA, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, CLYM, AURA, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CHRS, CLYM, AURA, and DBVT Company Descriptions

Aura Biosciences NASDAQ:AURA

Coherus Oncology NASDAQ:CHRS

Climb Bio NASDAQ:CLYM

DBV Technologies NASDAQ:DBVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, CLYM, AURA, and DBVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, CLYM, AURA, and DBVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, CLYM, AURA, and DBVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CHRS, CLYM, AURA, and DBVT Company Descriptions

Aura Biosciences NASDAQ:AURA

Coherus Oncology NASDAQ:CHRS

Climb Bio NASDAQ:CLYM

DBV Technologies NASDAQ:DBVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools